Brokerages Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $401.00

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been given an average rating of “Moderate Buy” by the thirteen research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $389.1818.

ONC has been the subject of several analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $405.00 target price on shares of BeOne Medicines in a report on Thursday, January 8th. Royal Bank Of Canada lifted their price target on BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, January 21st. Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and reduced their price objective for the company from $420.00 to $290.00 in a research note on Monday. Finally, Sanford C. Bernstein upgraded shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price for the company in a report on Monday, January 12th.

BeOne Medicines Trading Down 0.8%

Shares of NASDAQ:ONC opened at $287.33 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.08 and a current ratio of 3.41. The stock has a market capitalization of $31.51 billion, a price-to-earnings ratio of 114.02 and a beta of 0.53. BeOne Medicines has a 1-year low of $196.45 and a 1-year high of $385.22. The company has a 50 day moving average price of $333.24 and a 200 day moving average price of $329.71.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($1.02). The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. On average, research analysts anticipate that BeOne Medicines will post -5.82 EPS for the current fiscal year.

Insider Activity at BeOne Medicines

In related news, SVP Chan Henry Lee sold 341 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $300.00, for a total value of $102,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 2,665 shares of company stock valued at $902,792. 6.62% of the stock is currently owned by corporate insiders.

Institutional Trading of BeOne Medicines

Large investors have recently added to or reduced their stakes in the company. EFG International AG purchased a new stake in shares of BeOne Medicines in the fourth quarter valued at $25,000. Anchor Investment Management LLC acquired a new stake in shares of BeOne Medicines in the second quarter worth $26,000. Leonteq Securities AG purchased a new position in shares of BeOne Medicines during the fourth quarter valued at $35,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines during the second quarter valued at $35,000. Finally, CWM LLC raised its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.